Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property
PP Pagare, A Rastegar, O Abdulmalik… - Expert opinion on …, 2022 - Taylor & Francis
Introduction Sickle cell disease (SCD) is a debilitating inherited disorder that affects millions
worldwide. Four novel SCD therapeutics have been approved, including the hemoglobin …
worldwide. Four novel SCD therapeutics have been approved, including the hemoglobin …
Use of senicapoc for treatment of stroke
R Staal, J Weinstein, T Moller - US Patent 11,395,807, 2022 - Google Patents
Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major
component of stroke pathophysiology. The calcium activated potassium channel K Ca 3.1 is …
component of stroke pathophysiology. The calcium activated potassium channel K Ca 3.1 is …
Use of senicapoc for treatment of stroke
RGW STAAL, JR WEINSTEIN, T Möller - 2018 - Google Patents
Stroke is the leading cause of serious long-term disability and the fifth leading cause of
death in the United States (Mozaffarian et al., 2015). Treatment options for stroke are few in …
death in the United States (Mozaffarian et al., 2015). Treatment options for stroke are few in …